Next Article in Journal
Tempol Preserves Endothelial Progenitor Cells in Male Mice with Ambient Fine Particulate Matter Exposure
Previous Article in Journal
Treatment with Pulsed Extremely Low Frequency Electromagnetic Field (PELF-EMF) Exhibit Anti-Inflammatory and Neuroprotective Effect in Compression Spinal Cord Injury Model
 
Search for Articles:
Title / Keyword
Author / Affiliation
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
Journals
Biomedicines
Volume 10
Issue 2
10.3390/biomedicines10020324
biomedicines-logo
Submit to this Journal Review for this Journal Edit a Special Issue
► Article Menu

Article Menu

share announcement question_answer thumb_up
...
textsms
...
Article

Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis

by
Janne W. Bolt
1,2,
Arno W. van Kuijk
2,3,
Marcel B. M. Teunissen
4,
Dennis van der Coelen
1,2,
Saïda Aarrass
1,2,
Daniëlle M. Gerlag
1,2,
Paul P. Tak
1,2,5,6,
Marleen G. van de Sande
1,2,
Maria C. Lebre
7,† and
Lisa G. M. van Baarsen
1,2,*,†
1
Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology & Immunology Center (ARC), Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
2
Department of Rheumatology, Amsterdam Rheumatology & Immunology Center (ARC)-Reade, 1040 HG Amsterdam, The Netherlands
3
Department of Rheumatology, Reade, 1056 AB Amsterdam, The Netherlands
4
Department of Dermatology, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
5
Candel Therapeutics, Needham, MA 02494, USA
6
Internal Medicine, Cambridge University, Cambridge CB2 1TN, UK
7
The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Academic Editor: Mario Dell’Agli
Biomedicines 2022, 10(2), 324; https://doi.org/10.3390/biomedicines10020324
Received: 20 December 2021 / Revised: 19 January 2022 / Accepted: 24 January 2022 / Published: 29 January 2022
(This article belongs to the Section Immunology and Immunotherapy)
View Full-Text Download PDF
Browse Figures

Abstract

Interleukin (IL)-17 and tumor necrosis factor-alpha (TNF)-α are key players in psoriatic arthritis (PsA) pathogenesis. While both cytokines can be therapeutically targeted with beneficial clinical outcome, it is unclear whether inhibiting one cytokine will affect the other at sites of inflammation. If both act independently, this might provide a rationale for dual or combined inhibition of both cytokines. Here, we evaluated the effect of TNF blockade in PsA patients on IL-17 levels in both skin and synovial tissue biopsies. PsA patients with mild psoriatic skin lesions were randomized to receive either adalimumab or placebo for four weeks. Synovial and skin biopsies were obtained at weeks zero and four. Skin from healthy donors (HDs) was used for comparison. Expression of IL-17A, IL-17F, IL-17RA and IL-17RC was assessed by immunohistochemistry and analyzed with digital image analysis. We found relatively low levels of IL-17 and its receptors in the skin of PsA patients compared to HD, and only IL-17F in the dermis of lesional psoriatic skin was significantly higher compared to HD skin (p = 0.0002). Histologically IL-17A, IL-17F, IL-17RA and IL-17RC in skin and synovial tissue were not downregulated by adalimumab treatment. Thus, in this cohort of PsA patients with mild psoriasis, TNF blockade did not affect the protein levels of IL-17 cytokines and its receptors in skin and synovium, despite reduced cellular inflammation and improved clinical outcome for joint involvement. View Full-Text
Keywords: psoriatic arthritis; skin; synovium; interleukin-17; adalimumab; immunopathogenesis; immunohistochemistry psoriatic arthritis; skin; synovium; interleukin-17; adalimumab; immunopathogenesis; immunohistochemistry
►▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
SciFeed

Share and Cite

MDPI and ACS Style

Bolt, J.W.; van Kuijk, A.W.; Teunissen, M.B.M.; van der Coelen, D.; Aarrass, S.; Gerlag, D.M.; Tak, P.P.; van de Sande, M.G.; Lebre, M.C.; van Baarsen, L.G.M. Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines 2022, 10, 324. https://doi.org/10.3390/biomedicines10020324

AMA Style

Bolt JW, van Kuijk AW, Teunissen MBM, van der Coelen D, Aarrass S, Gerlag DM, Tak PP, van de Sande MG, Lebre MC, van Baarsen LGM. Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis. Biomedicines. 2022; 10(2):324. https://doi.org/10.3390/biomedicines10020324

Chicago/Turabian Style

Bolt, Janne W., Arno W. van Kuijk, Marcel B.M. Teunissen, Dennis van der Coelen, Saïda Aarrass, Daniëlle M. Gerlag, Paul P. Tak, Marleen G. van de Sande, Maria C. Lebre, and Lisa G.M. van Baarsen. 2022. "Impact of Adalimumab Treatment on Interleukin-17 and Interleukin-17 Receptor Expression in Skin and Synovium of Psoriatic Arthritis Patients with Mild Psoriasis" Biomedicines 10, no. 2: 324. https://doi.org/10.3390/biomedicines10020324

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Map by Country/Region

1
Back to TopTop